Back to today’s briefing

Story perspectives

Promising MAFLD Therapies Face Access and Cost Hurdles

1/4/2025

27 6

Summary

Story summary

New therapies for metabolic dysfunction-associated fatty liver disease (MAFLD), such as resmiterone and GLP-1 receptor agonists, are making strides in reducing liver inflammation and fibrosis. Yet, the high costs and insurance hurdles hinder patient access. While these emerging treatments hold promise, more research is essential to unlock their full potential in preventing serious liver complications.

1 of 1

Story summary

New therapies for metabolic dysfunction-associated fatty liver disease (MAFLD), such as resmiterone and GLP-1 receptor agonists, are making strides in reducing liver inflammation and fibrosis. Yet, the high costs and insurance hurdles hinder patient access. While these emerging treatments hold promise, more research is essential to unlock their full potential in preventing serious liver complications.